Glucophage in Polycystic Ovaries Treatment: Pros and Cons

Glucophage, a brand of the drug Metmorfin, has been on the European market for a quarter century, but it has been widely distributed in theUS only since 1995, and FDA approved only for type-2 diabetes. 

Insulin resistance is one cause of PCOS (polycystic ovaries syndrome) or the ovarian cyst syndrome, and the impaired ability of the body to take glucose from the bloodstream for absorption in muscles and tissues. That's a serious disability, affecting the bodily system's overall health and energy levels, especially with multiple cysts also taking their toll (as in PCOS). And this is where Metmorfin provides a highly effective remedy.

Originally developed to counter the high blood glucose in type-2 diabetes, Metmorfin compensates for this disability. Its insulin-friendly action limits the intestinal absorption of dietary carbohydrates as well as the liver's production of insulin. It thereby limits the loss of blood sugar reserves.

By boosting muscle cell sensitivity to insulin, it helps move more glucose into muscle tissue with lower expense of insulin. By controlling both the insulin and glucose levels, it prevents infertility , obesity, heart disease and some cancers as well.

Polycystic ovaries are those where there are many cysts. Having one cyst at a time, especially one that is growing rapidly is quite bad. Body chemistry that causes many cysts to form rapidly is worse.

With Glucophage, polycystic ovaries get substantial relief on the insulin front, but not without substantial costs by way of a range of grave contraindications.